| Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer AK Singh, M Praharaj, KA Lombardo, T Yoshida, A Matoso, AS Baras, ... Nature communications 13 (1), 878, 2022 | 41 | 2022 |
| Bacillus Calmette-Guerin overexpressing an endogenous stimulator of interferon genes agonist provides enhanced protection against pulmonary tuberculosis RJ Dey, B Dey, AK Singh, M Praharaj, W Bishai The Journal of infectious diseases 221 (7), 1048-1056, 2020 | 33 | 2020 |
| 124I-Iodo-DPA-713 positron emission tomography in a hamster model of SARS-CoV-2 infection CA Ruiz-Bedoya, F Mota, AA Ordonez, CA Foss, AK Singh, M Praharaj, ... Molecular Imaging and Biology 24 (1), 135-143, 2022 | 14 | 2022 |
| Recombinant BCG overexpressing STING agonist elicits trained immunity and improved antitumor efficacy in non-muscle invasive bladder cancer AK Singh, M Praharaj, KA Lombardo, T Yoshida, A Matoso, AS Baras, ... Urologic Oncology: Seminars and Original Investigations 38 (12), 899, 2020 | 10 | 2020 |
| Relative and Quantitative Phosphoproteome Analysis of Macrophages in Response to Infection by Virulent and Avirulent Mycobacteria Reveals a Distinct Role of the Cytosolic … E Choudhary, CK Bullen, R Goel, AK Singh, M Praharaj, P Thakur, ... Journal of proteome research 19 (6), 2316-2336, 2020 | 8 | 2020 |
| Dynamic single-cell RNA sequencing reveals BCG vaccination curtails SARS-CoV-2 induced disease severity and lung inflammation AK Singh, R Wang, KA Lombardo, M Praharaj, CK Bullen, P Um, S Davis, ... bioRxiv, 2022 | 7 | 2022 |
| Paradigm shift in transmission of vector borne diseases US Singh, M Praharaj, C Sharma, A Das Journal of Emerging Infectious Diseases 1 (4), 2016 | 6 | 2016 |
| Intravenous BCG vaccination reduces SARS-CoV-2 severity and promotes extensive reprogramming of lung immune cells AK Singh, R Wang, KA Lombardo, M Praharaj, CK Bullen, P Um, M Gupta, ... Iscience 26 (10), 2023 | 4 | 2023 |
| BCG overexpressing an endogenous STING agonist provides enhanced protection against pulmonary tuberculosis RJ Dey, B Dey, AK Singh, M Praharaj, W Bishai bioRxiv, 365411, 2018 | 4 | 2018 |
| Varying Treatment outcomes of small molecule STING Agonist ADU-S100 in intratumoral and intravesical treatment regimens in syngeneic murine MB49 and in the N-methyl-N … AK Singh, K Lombardo, M Praharaj, J Liu, R Becker, K Harris, M Kates, ... Cancer Research 82 (12_Supplement), 3511-3511, 2022 | 1 | 2022 |
| PD53-11 DIVERGENT THERAPEUTIC OUTCOMES OF STING AGONIST ADU-S100 IN INTRATUMORAL AND INTRAVESICAL TREATMENT REGIMENS IN SYNGENEIC MURINE MB49 AND IN THE N-METHYL-N-NITROSOUREA … AK Singh, K Lombardo, M Praharaj, J Liu, R Becker, K Harris, M Kates, ... The Journal of Urology 207 (Supplement 5), e914, 2022 | 1 | 2022 |
| Recombinant therapeutic interventions for cancer WR Bishai, TJ Bivalacqua, AK Singh, M Praharaj, T Yoshida US Patent App. 16/638,943, 2021 | 1 | 2021 |
| MP57-02 “NEXT-GEN STING-AGONIST LIKE BCG CONFERS ENHANCED IMMUNOGENICITY AND ANTITUMOR EFFICACY IN VITRO AND IN VIVO” A Singh*, M Praharaj, G Joice, T Yoshida, M Kates, D McConkey, ... The Journal of Urology 201 (Supplement 4), e813-e813, 2019 | 1 | 2019 |
| Targeting of macrophage PI3Kγin prostate cancer using Eganelisib (IPI-549) reprograms immune-suppressive infiltrating macrophages to enhance anti-tumor immune responses and … KM Adusei, TR Nirschl, AJ Lee, F Shen, X Wang, M Praharaj, J Alvarez, ... Cancer Research 84 (6_Supplement), 170-170, 2024 | | 2024 |
| Targeting immunosuppressive TREM2+tumor associated macrophages in prostate cancer AJ Lee, K Adusei, M Praharaj, F Shen, X Wang, K Bhatia, T Nirschl, ... Cancer Research 84 (6_Supplement), 3923-3923, 2024 | | 2024 |
| Targeting CD47/SIRPɑ axis in urologic cancer triggers enhanced phagocytosis of tumor cell and induces tumor growth inhibition F Shen, M Praharaj, AJ Lee, TR Nirschl, X Wang Cancer Research 84 (6_Supplement), 1374-1374, 2024 | | 2024 |
| Abstract A079: Glutamine antagonist prodrug JHU083 reprograms immunosuppressive tumor-associated macrophages to drive tumor immunity in urologic cancers M Praharaj, F Shen, AJ Lee, L Zhao, TR Nirschl, X Wang, D Theodros, ... Cancer Research 83 (11_Supplement), A079-A079, 2023 | | 2023 |
| Glutamine antagonist prodrug JHU083 reprograms immunosuppressive tumor-associated macrophages (TAMs) to drive tumor immunity in urologic cancers M Praharaj, F Shen, AJ Lee, L Zhao, T Nirschl, X Wang, D Theodros, ... Cancer Research 83 (7_Supplement), 6432-6432, 2023 | | 2023 |
| TARGETING GLUTAMINE METABOLISM AND CD47-SIRP ALPHA SIGNALING REPROGRAMS IMMUNOSUPPRESSIVE TUMOR-ASSOCIATED MACROPHAGES RESULTING IN IMPROVED ANTI-TUMOR IMMUNITY M Praharaj Johns Hopkins University, 2023 | | 2023 |
| Recombinant therapeutic interventions for cancer WR Bishai, TJ Bivalacqua, A Singh, M Praharaj, T Yoshida US Patent App. 17/797,055, 2023 | | 2023 |
William BishaiProfessor of Medicine, Johns Hopkins UniversityE-mail megerősítve itt: jhmi.edu
